Breaking News Instant updates and real-time market news.

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45

Alexion call volume above normal and directionally bullish

Bullish option flow detected in Alexion with 5,652 calls trading, 12x expected, and implied vol increasing over 2 points to 46.59%. Nov-19 105 calls and Oct-19 95 calls are the most active options, with total volume in those strikes near 4,800 contracts. The Put/Call Ratio is 0.05. Earnings are expected on October 23rd.

  • 19

    Oct

  • 23

    Oct

ALXN Alexion
$99.63

0.37 (0.37%)

09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.
09/18/19
RBCM
09/18/19
NO CHANGE
RBCM
Outperform
RBC Capital sees Dr. Sarin as strong successor in Alexion CFO role
RBC Capital analyst Kennen MacKay keeps his Outperform rating on Alexion after the company's surprise announcement that its CFO Paul Clancy is stepping down. The analyst notes that his follow-up discussions with the management suggest that the departure of Mr. Clancy was not related to an alternative role in the industry but rather his plans to pursue non-operational roles. MacKay adds that Alexion intends to maintain its focus on execution, including the conversion of Soliris-treated patients to next-generation Ultomiris, and sees the incoming CFO Aradhana Sarin as a "strong successor" given her prior role as a SVP in Business Development.
09/26/19
WBLR
09/26/19
INITIATION
WBLR
Outperform
Alexion initiated with an Outperform, $146 fair value at William Blair
William Blair analyst Raju Prasad earlier today initiated coverage of Alexion Pharmaceuticals with an Outperform rating and $146 fair value estimate. The shares have been weak because of Alexion's intellectual property issues in the United States and Europe and the threat from competitive products to the durability of its complement franchise, Prasad tells investors in a research note. The analyst, however, believes Alexion will remain the leader in atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with its Ultomiris transition. This should be supplemented by the continued launch and potential market expansion in generalized myesthenia gravis and the neuromyelitis optica spectrum disorder launch beginning in the United States in the second half of 2019, says Prasad. He sees current valuation levels as a positive risk/reward setup.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.

TODAY'S FREE FLY STORIES

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24
Hot Stocks
Amarin raises guidance after FDA approves Vascepa »

Amarin (AMRN) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

, LEA

Lear

$129.43

-0.84 (-0.64%)

17:22
12/13/19
12/13
17:22
12/13/19
17:22
Hot Stocks
Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 »

Grand Canyon Education…

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

RTN

Raytheon

$217.31

-0.93 (-0.43%)

17:20
12/13/19
12/13
17:20
12/13/19
17:20
Hot Stocks
Raytheon awarded $123.53M Navy contract modification »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

17:19
12/13/19
12/13
17:19
12/13/19
17:19
Hot Stocks
Live Nation, Zebra Technologies, Steris to move to S&P 500 at open on 12/23 »

Live Nation (LYV), Zebra…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BAESY

BAE Systems

$0.00

(0.00%)

17:15
12/13/19
12/13
17:15
12/13/19
17:15
Hot Stocks
BAE Systems awarded $249.15M Army contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$146.32

-0.14 (-0.10%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Hot Stocks
West Pharmaceutical announces 848K share repurchase authorization »

On December 10, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Earnings
Amarin sees FY20 revenue $650M-$700M, consensus $654.55M »

With respect to 2020,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

IBIO

iBio

$0.22

-0.0179 (-7.43%)

17:01
12/13/19
12/13
17:01
12/13/19
17:01
Hot Stocks
iBio receives NYSE noncompliance notice »

iBio, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLT

Applied Therapeutics

$21.23

0.29 (1.38%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Syndicate
Breaking Syndicate news story on Applied Therapeutics »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Earnings
Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M 

FY19 consensus $410.25M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

BIO

Bio-Rad

$354.69

-8.005 (-2.21%)

16:56
12/13/19
12/13
16:56
12/13/19
16:56
Hot Stocks
Bio-Rad progressing from ransomware attack recovery detected on Dec 5th »

Bio-Rad Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:50
12/13/19
12/13
16:50
12/13/19
16:50
Hot Stocks
Amarin confirms FDA approval of Vascepa »

Amarin announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

FRTA

Forterra

$10.69

0.11 (1.04%)

16:46
12/13/19
12/13
16:46
12/13/19
16:46
Syndicate
Breaking Syndicate news story on Forterra »

Forterra files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:45
12/13/19
12/13
16:45
12/13/19
16:45
Hot Stocks
Amarin receives FDA approval of Vascepa »

The U.S. FDA approved the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

, SPX

S&P 500

$0.00

(0.00%)

16:37
12/13/19
12/13
16:37
12/13/19
16:37
Periodicals
SCOTUS to hear three cases on Trump's financial records, CNBC reports »

The U.S. Supreme Court…

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.